Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 14/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362266 | 0.85 | HDAC3 (0.46) | PAK1TLK2HDAC3HDAC4HDAC1 | |
| SCHEMBL5369667 | 0.84 | HDAC3 (0.65) | PAK1TLK2HDAC3HDAC4HDAC1 | |
| SCHEMBL5373331 | 0.82 | TLK2 (0.67) | TLK2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5366320 | 0.79 | FLT3 (0.54) | TLK2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8429168 | 0.78 | PAK1 (0.68) | PAK1TLK2HDAC3HDAC4HDAC1 | |
| SCHEMBL8429175 | 0.78 | PAK1 (0.68) | PAK1TLK2HDAC3HDAC4HDAC1 | |
| SCHEMBL8411247 | 0.77 | MAPK1 (0.70) | PAK1TLK2ROCK2PDGFRBKDR | |
| SCHEMBL8411239 | 0.77 | MAPK1 (0.70) | PAK1TLK2ROCK2PDGFRBKDR | |
| SCHEMBL5358704 | 0.76 | AKT2 (0.60) | — | |
| SCHEMBL5364317 | 0.74 | AKT2 (0.48) | TLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PAK1 427/4885TLK2 48/4885HDAC3 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.